Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Aims: Exenatide has been demonstrated to improve glycaemic control in patients with type 2 diabetes, with no effect on heart rate corrected QT (QT c) at therapeutic concentrations. This randomized, placebo‐ and positive‐controlled, crossover, thorough QT study evaluated the effects of therapeutic and supratherapeutic exenatide concentrations on QT c. Methods: Intravenous infusion was employed to achieve steady‐state supratherapeutic concentrations in healthy subjects within a reasonable duration (i.e. days). Subjects received exenatide, placebo and moxifloxacin, with ECGs recorded pre‐therapy and during treatment. Intravenous exenatide was expected to increase heart rate to a greater extent than subcutaneous twice daily or once weekly formulations. To assure proper heart rate correction, a wide range of baseline heart rates was assessed and prospectively defined methodology was applied to determine the optimal QT correction. Results: Targeted steady‐state plasma exenatide concentrations were exceeded (geometric mean ± SEM 253 ± 8.5 pg ml−1, 399 ± 11.9 pg ml−1 and 627 ± 21.2 pg ml−1). QT c P, a population‐based method, was identified as the most appropriate heart rate correction and was prespecified for primary analysis. The upper bound of the two‐sided 90% confidence interval for placebo‐corrected, baseline‐adjusted QT c P (ΔΔ QT c P) was <10 ms at all time points and exenatide concentrations. The mean of three measures assessed at the highest steady‐state plasma exenatide concentration of ∼500 pg ml−1 (ΔΔ QT c Pavg) was −1.13 [−2.11, −0.15). No correlation was observed between ΔΔ QT c P and exenatide concentration. Assay sensitivity was confirmed with moxifloxacin. Conclusions: These results demonstrated that exenatide, at supratherapeutic concentrations, does not prolong QT c and provide an example of methodology for QT assessment of drugs with an inherent heart rate effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Experimental designs balanced for the estimation of residual effects of treatments
Williams, E. (1949) · Australian Journal of Scientific Research Series A Physical Sciences · doi:10.1071/ch9490149 · Cited by 1,104
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Self-citationKlonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699
Blevins, T., Pullman, J., Malloy, J., Yan, P., Taylor, K., Schulteis, C., Trautmann, M., & Porter, L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2081 · Cited by 448
Self-citationDiamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60406-0 · Cited by 434
Chatterjee, D. J., Khutoryansky, N., Zdravkovic, M., Sprenger, C. R., & Litwin, J. S. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009339189 · Cited by 54
Cited by
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Differential effects of glucagon-like peptide-1 receptor agonists on heart rate
Lorenz, M., Lawson, F., Owens, D., Raccah, D., Roy-Duval, C., Lehmann, A., Perfetti, R., & Blonde, L. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0490-6 · Cited by 166
Seufert, J., & Gallwitz, B. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12251 · Cited by 156
Schmitt, C., Portron, A., Jadidi, S., Sarkar, N., & DiMarchi, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13024 · Cited by 74
GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms
Mullur, N., Morissette, A., Morrow, N. M., & Mulvihill, E. E. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0046 · Cited by 51
Metadata
- Authors
- Darpö, B., Philip, S., MacConell, L., Cirincione, B., Mitchell, M., Han, J., Huang, W., Malloy, J., Schulteis, C., Shen, L., & Porter, L.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2013-03-15
- Volume
- 75
- Issue
- 4
- Pages
- 979-989
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W1898466139
- Cited by
- 35
- References
- 8
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects. https://app.cochat.ai/papers/10.1111/j.1365-2125.2012.04416.x
- The paper
- Darpö, B., Philip, S., MacConell, L., Cirincione, B., Mitchell, M., Han, J., Huang, W., Malloy, J., Schulteis, C., Shen, L., & Porter, L. (2013). Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2012.04416.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.